Dupilumab für jede Typ-2-Inflammation einsetzbar
Crossref DOI link: https://doi.org/10.1007/s15007-022-5634-2
Published Online: 2022-10-31
Published Print: 2022-11
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Mosler, Nana
Text and Data Mining valid from 2022-10-31
Version of Record valid from 2022-10-31
Article History
First Online: 31 October 2022